Mumbai: Cancer drugs maker Dabur Pharma Ltd said on 24 October it signed a deal with Spain’s Combino Pharm for marketing the Indian firm’s generic cancer products in that country.
Combino will initially sell three of Dabur’s products that already have the UK marketing approval, Dabur said in a statement.
The size of Spain’s oncology generic market cannot be readily estimated, but it could constitute about 10% of the country’s overall generic market, pegged at $750 million, Dabur’s Chief Executive Officer Ajay Kumar Vij told Reuters.
“It will be a rapidly growing market because the generic penetration in Spain is very low currently,” he said.
Dabur will manufacture these drugs at its UK and Indian facilities, he added.
Dabur shares were trading 0.6% higher at Rs63.70 in the Mumbai market.